Novo Nordisk | NVO - Gross Profit On Sales

Stock Price
47.64
Daily Change
4.32 9.97%
Monthly
-15.74%
Yearly
-44.86%
Q1 Forecast
56.42

Novo Nordisk reported DKK64.01B in Gross Profit on Sales for its fiscal quarter ending in June of 2025.





Gross Profit On Sales Change Date
ANI Pharmaceuticals USD 111.79M 1.68M Sep/2025
Aurora Cannabis CAD 32.29M 4.34M Sep/2025
Bausch Health Companies USD 1.93B 165M Sep/2025
Bristol-Myers Squibb USD 8.79B 110M Sep/2025
Canopy Growth CAD 21.9M 3.86M Sep/2025
Corcept Therapeutics USD 203.04M 12.04M Sep/2025
Drreddys Laboratories INR 46.81B 10.24B Dec/2025
Eli Lilly USD 14.59B 1.48B Sep/2025
GlaxoSmithKline GBP 6.18B 106M Dec/2025
Merck USD 13.42B 431M Sep/2025
Novartis USD 10.82B 695M Sep/2025
Novo Nordisk DKK 64.01B 1.19B Jun/2025
Novo Nordisk DKK 64.01B 1.19B Jun/2025
Pacira USD 130.92M 5M Sep/2025
Perrigo USD 377.1M 14.2M Sep/2025
Prestige Brands USD 157.37M 5.79M Dec/2025
Sanofi EUR 8.45B 1.31B Dec/2025
Supernus Pharmaceuticals USD 148.81M 21.01M Sep/2025
Zoetis USD 1.72B 96M Sep/2025